Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Pharmaceuticals
Abbott Licenses Kidney Disease Drug
by Lisa M. Jarvis
October 4, 2010
| A version of this story appeared in
Volume 88, Issue 40
Abbott Laboratories has agreed to pay $450 million for the right to sell Reata Pharmaceuticals’ bardoxolone outside the U.S. Bardoxolone is an oral antioxidant inflammatory modulator that turns on Nrf2, a protein that dictates the production of antioxidant and detoxification enzymes. The drug candidate has shown promise in two Phase II trials for chronic kidney disease, a condition affecting 30–40% of people with type 2 diabetes. The Abbott deal excludes some Asian markets, for which Kyowa Hakko Kirin has already licensed the drug.
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X